List of Excipients in Branded Drug ESOMEPRAZOLE SODIUM

« Back to Dashboard

Generic Drugs Containing ESOMEPRAZOLE SODIUM

Company	Ingredient	NDC	Excipient
Hainan Poly Pharm Co Ltd	esomeprazole sodium	14335-060	EDETATE DISODIUM
Hainan Poly Pharm Co Ltd	esomeprazole sodium	14335-060	SODIUM HYDROXIDE
Accord Healthcare Inc	esomeprazole sodium	16729-252	EDETATE DISODIUM
Accord Healthcare Inc	esomeprazole sodium	16729-252	SODIUM HYDROXIDE
Akorn	esomeprazole sodium	17478-850	EDETATE DISODIUM
Akorn	esomeprazole sodium	17478-850	SODIUM HYDROXIDE
Akorn	esomeprazole sodium	17478-850	WATER

What are the Most Frequently-Used Excipients in ESOMEPRAZOLE SODIUM?

# Of NDCs	Excipient
7	EDETATE DISODIUM
7	SODIUM HYDROXIDE
2	WATER

Esomeprazole Sodium Excipient Strategy and Commercial Opportunities

Last updated: October 16, 2026

Esomeprazole sodium is an injectable proton-pump inhibitor used when oral administration is unsuitable. The strongest commercial opportunities are in ready-to-use intravenous presentations, hospital-premix formats, improved container-closure systems, and lower-cost generic products that preserve chemical stability while reducing preparation time. The core formulation challenge is maintaining esomeprazole stability in an alkaline environment without creating excessive sodium load, precipitation, particulate risk, or administration complexity.

What is the pharmaceutical role of esomeprazole sodium?

Esomeprazole is the S-isomer of omeprazole. Esomeprazole sodium is used primarily for intravenous formulations because the salt provides sufficient aqueous handling characteristics for reconstitution and injection.

The reference intravenous product, Nexium I.V., is supplied as a sterile lyophilized powder for reconstitution. FDA labeling identifies esomeprazole sodium as the active ingredient and lists disodium edetate and sodium hydroxide among the inactive ingredients. The final reconstituted solution is alkaline, with the pH controlled to support stability.[1]

Attribute	Esomeprazole sodium
Therapeutic class	Proton-pump inhibitor
Primary injectable use	Short-term IV treatment when oral therapy is not appropriate
Reference product	Nexium I.V.
Dosage form	Sterile lyophilized powder for solution
Common vial strength	40 mg esomeprazole equivalent
Administration	Intravenous injection or infusion after reconstitution
Key formulation issue	Acid-labile benzimidazole chemistry
Main excipient functions	Chelation, pH adjustment, stability control
Principal commercial channel	Hospitals, outpatient infusion, institutional procurement

Esomeprazole is acid-labile. Exposure to low pH causes degradation, which is why oral products use enteric protection and injectable products use alkaline formulation conditions. The excipient strategy for the sodium salt therefore differs materially from the strategy used for esomeprazole magnesium delayed-release capsules.

What excipients are used in esomeprazole sodium injection?

The reference formulation uses a limited excipient system centered on pH control and metal-ion management.

Disodium edetate

Disodium edetate, also known as disodium EDTA, is used as a chelating agent. It can bind trace metal ions that catalyze oxidative or other degradation pathways. Its value is highest where the drug substance, water, elastomer components, glass, or manufacturing equipment can introduce low concentrations of metals.

The commercial advantages of disodium edetate include:

• Low use level.
• Established parenteral precedent.
• Compatibility with alkaline injectable systems.
• Potential reduction in trace-metal-driven degradation.
• Limited impact on osmolality at the quantities generally used.

The formulation must control EDTA concentration carefully. Excessive chelator levels can create regulatory, toxicological, and compatibility concerns without producing proportional stability gains.

Sodium hydroxide

Sodium hydroxide adjusts the formulation to an alkaline pH. It is normally used in a quantity sufficient to reach the target pH rather than as a fixed high-dose excipient.

Its commercial function is central because esomeprazole stability is highly pH-dependent. The product must balance three factors:

1. Adequate alkalinity to slow degradation.
2. Acceptable local tolerability during injection.
3. Compatibility with the vial, stopper, infusion system, and co-administered fluids.

The pH adjustment step must be tightly controlled. Small changes can affect degradation rate, precipitation behavior, osmolality, and the final administration profile.

Water for injection

Water for injection is used during manufacture and reconstitution. It is not normally the differentiating excipient, but its quality directly affects stability, endotoxin control, particulate performance, and microbial risk.

Sodium chloride and buffering agents

Sodium chloride or a separate buffer may be relevant to alternative presentations, particularly ready-to-use infusion bags. These ingredients are not automatically interchangeable with the reference lyophilized-vial system. Increasing ionic strength can affect solubility, degradation kinetics, osmolality, and container compatibility.

A commercial developer should not add phosphate, citrate, acetate, or other buffer systems solely to improve pH control without demonstrating compatibility and stability. Buffer selection can create new precipitation, interaction, and regulatory burdens.

What formulation strategy best protects esomeprazole sodium?

The primary strategy is to maintain an alkaline microenvironment while limiting water exposure during storage.

Lyophilized vial strategy

A lyophilized vial remains the lowest-risk development route because it separates long-term storage from the aqueous state. The formulation can be designed around:

• A sterile drug substance or sterile bulk solution.
• Controlled sodium hydroxide adjustment.
• Disodium EDTA at a justified concentration.
• Low residual moisture.
• A stopper and seal compatible with alkaline conditions.
• Reconstitution instructions that minimize preparation error.

The principal disadvantages are hospital labor, reconstitution variability, vial overfill requirements, and the risk of incorrect dilution or administration.

Ready-to-use solution strategy

A ready-to-use solution could create commercial differentiation by eliminating reconstitution. The product could be offered in an infusion bag, syringe, or small-volume container.

This approach faces higher technical risk because the drug remains exposed to water throughout shelf life. Development work must establish:

• Long-term chemical stability.
• Photostability.
• Oxidative stability.
• Subvisible and visible particulate control.
• Container-closure extractables and leachables.
• Compatibility with infusion tubing and connectors.
• In-use stability after opening or attachment.
• Stability after dilution into commonly used infusion fluids.

A ready-to-use product has the greatest potential to reduce hospital preparation time, but it also has the highest probability of requiring a novel formulation or packaging solution.

Dual-chamber and reconstitution-device strategy

A dual-chamber container or integrated reconstitution device can preserve the stability of a dry product while reducing handling steps. The product may combine:

• A dry esomeprazole sodium compartment.
• A sterile diluent compartment.
• A transfer mechanism activated before administration.

This approach can be commercially attractive where hospitals value workflow simplification but a fully liquid product does not achieve acceptable shelf life.

What dosage forms and delivery systems are commercially attractive?

Presentation	Technical risk	Hospital convenience	Differentiation potential
Lyophilized vial	Low to moderate	Low	Low
Premixed infusion bag	High	High	High
Ready-to-use syringe	High	High	High
Dual-chamber vial	Moderate to high	Moderate to high	Moderate
Small-volume vial with standardized diluent	Moderate	Moderate	Moderate
Closed-system transfer format	Moderate	High	High

The most practical near-term opportunity is a robust generic lyophilized vial with reduced reconstitution burden. The highest-value opportunity is a ready-to-use or premixed product supported by a defensible stability and container-closure package.

What manufacturing and excipient barriers affect commercial entry?

Sterility and aseptic processing

Esomeprazole sodium injection requires validated sterile manufacturing, particulate control, endotoxin control, and container-closure integrity. A lyophilized product may require aseptic filling followed by freeze-drying. A ready-to-use solution may require sterile filtration, aseptic filling, or terminal sterilization if the formulation and container can tolerate the process.

Terminal sterilization is generally more difficult for degradation-sensitive products. The manufacturing process must therefore be evaluated as part of the formulation strategy rather than after formulation selection.

Freeze-drying cycle

For a lyophilized product, the cycle must achieve:

• Uniform residual moisture.
• Acceptable cake structure.
• Rapid and complete reconstitution.
• Limited collapse or meltback.
• Consistent vial-to-vial potency.
• Shelf-life stability under labeled storage conditions.

The excipient system may require a bulking agent or other lyoprotectant in an alternative product, but any added excipient increases the burden for compatibility, particulate testing, and regulatory justification.

Container-closure compatibility

Alkaline formulations can interact with glass, rubber closures, coatings, and plastics. The development program should assess:

• Glass delamination.
• Alkali extraction.
• Stopper swelling.
• Adsorption or absorption.
• Silicone oil interaction.
• Extractables and leachables.
• Closure integrity after shipping and temperature cycling.

For ready-to-use products, the container is part of the formulation. A technically stable drug solution can fail commercially if the bag, syringe, tubing, or closure introduces unacceptable leachables or loses integrity.

What patents protect esomeprazole sodium formulations?

Esomeprazole patent analysis must distinguish among the active ingredient, salt form, injectable formulation, oral dosage form, manufacturing process, and method of treatment. The relevant rights may include:

• Esomeprazole compound and stereochemical composition patents.
• Esomeprazole sodium salt patents.
• Injectable solution or lyophilized formulation patents.
• Stabilized aqueous formulation patents.
• Manufacturing and purification processes.
• Method-of-use patents for gastrointestinal bleeding or acid-related disorders.
• Device or container patents covering premixed administration systems.

The original branded esomeprazole estate was developed by AstraZeneca. Core compound and early product protections have generally reached expiration in major markets, allowing generic competition. Current risk is more likely to arise from later formulation, manufacturing, device, or method-of-use rights than from the basic active ingredient.

Patent freedom-to-operate should be performed separately for:

1. A conventional 40 mg lyophilized vial.
2. A ready-to-use infusion bag.
3. A prefilled syringe.
4. A dual-chamber container.
5. A new stabilizer or chelator combination.
6. A specific indication or dosing regimen.

An alternative excipient system can reduce infringement exposure, but it does not automatically avoid formulation patents. A formulation patent may cover a pH range, excipient concentration, stability threshold, container, or administration method rather than a specific trade-name product.

What is the FDA regulatory status of esomeprazole sodium?

Esomeprazole sodium injection is regulated as a prescription drug product under an abbreviated or full application pathway, depending on the applicant’s product and reference-product strategy. The FDA reference product is Nexium I.V. The agency evaluates injectable products closely for sterility, particulate matter, impurities, stability, container closure, and labeling.[1][2]

Relevant regulatory considerations include:

• Demonstration of pharmaceutical equivalence.
• Matching strength and route of administration.
• Injectable quality and sterility controls.
• Reconstitution and dilution instructions.
• In-use stability.
• Labeling of storage conditions.
• Compatibility with permitted diluents.
• Extractables and leachables.
• Comparative impurity profiles.

The Orange Book should be checked for current patents and regulatory exclusivity associated with the specific reference product and dosage form. Orange Book status can differ between oral esomeprazole products and esomeprazole sodium injection products.[3]

When does esomeprazole sodium lose exclusivity?

The principal compound-level exclusivity for esomeprazole has expired in the major pharmaceutical markets. Generic competition is therefore technically and legally feasible for conventional injectable presentations, subject to current product-specific patent listings and regulatory requirements.

The practical exclusivity of an improved product may last longer than the active-ingredient exclusivity if the developer controls:

• A superior ready-to-use presentation.
• A proprietary container or transfer device.
• A stable liquid formulation.
• A differentiated hospital workflow.
• A formulation with extended room-temperature stability.
• A method-of-use indication not covered by existing generic labels.

These protections are usually narrower than compound patents and require evidence that the claimed formulation or use provides a legally relevant distinction.

Which companies are competing in esomeprazole sodium?

Competition includes the originator, established injectable-generic companies, hospital-contract suppliers, and manufacturers with sterile injectable capacity. The commercial field is shaped less by consumer brand recognition than by:

• FDA approval status.
• Availability during shortages.
• Hospital contracting.
• Unit price.
• Supply reliability.
• Vial configuration.
• Reconstitution burden.
• Quality history.
• Distribution reach.

Potential competitors include AstraZeneca through the Nexium franchise and generic injectable manufacturers such as Fresenius Kabi, Hikma, Sagent, and other approved suppliers, depending on the market and current listing status. Company participation must be verified against current FDA approvals and procurement data before investment or licensing decisions.

What generic launch scenarios exist?

Low-cost conventional generic

A conventional lyophilized vial can compete primarily on price and supply reliability. This is the most straightforward launch model but has limited differentiation.

Hospital-efficiency generic

A product with clearer reconstitution instructions, optimized vial fill, standardized diluent packaging, or a closed transfer system can target pharmacy labor and medication-error reduction.

Ready-to-use premium product

A stable infusion bag or syringe can command a higher price if it reduces pharmacy preparation and waste. Adoption depends on shelf life, reimbursement, compatibility, and supply-chain economics.

Shortage-replacement product

Injectable shortages can create rapid demand for qualified alternatives. The commercial benefit depends on manufacturing capacity, regulatory readiness, and the ability to maintain supply after the shortage ends.

How strong is the excipient and formulation IP opportunity?

The basic excipient combination of disodium EDTA and sodium hydroxide is unlikely to provide a durable standalone barrier because both ingredients are well established in pharmaceutical manufacturing. Stronger protection may arise from a specific combination of:

• Defined pH range.
• Chelator concentration.
• Impurity threshold.
• Reconstitution time.
• Long-term stability profile.
• Container material.
• Ready-to-use configuration.
• Reduced degradation under room-temperature storage.

A defensible patent should link the formulation variables to measurable technical results. Broad claims covering routine pH adjustment or generic chelation are more vulnerable to validity and obviousness challenges.

What revenue exposure does esomeprazole sodium create?

Esomeprazole sodium is a mature product with lower brand-driven pricing than during the initial Nexium exclusivity period. Revenue potential is concentrated in institutional volume rather than retail demand.

The most relevant commercial metrics are:

• Annual injectable units.
• Hospital formulary wins.
• Contract price per vial or bag.
• Manufacturing yield.
• Reconstitution labor savings.
• Product wastage.
• Back-order frequency.
• Gross margin after sterile manufacturing costs.
• Number of qualified suppliers.
• Share of patients requiring intravenous therapy.

A ready-to-use product can support higher pricing than a conventional vial, but the economic case must quantify avoided pharmacy labor, reduced medication waste, and lower preparation risk.

Key Takeaways

• Esomeprazole sodium injection depends on alkaline pH control and protection from trace-metal-driven degradation.
• Disodium EDTA and sodium hydroxide are the core excipient tools in the reference injectable formulation.
• Lyophilized vials offer the lowest technical and regulatory risk.
• Ready-to-use bags, syringes, and dual-chamber systems offer the highest differentiation potential.
• Container-closure compatibility is a major development issue for alkaline liquid products.
• Core esomeprazole compound exclusivity has expired in major markets, but later formulation, device, manufacturing, and method-of-use rights require product-specific review.
• The strongest commercial opportunity is a stable, workflow-efficient injectable presentation supported by reliable sterile manufacturing.
• Excipient composition alone is unlikely to create strong exclusivity unless linked to defined stability, impurity, packaging, or administration advantages.

FAQs

Can esomeprazole sodium injection use the same excipients as esomeprazole magnesium capsules?

No. Oral esomeprazole magnesium products rely on enteric protection and solid-dose excipients, while injectable esomeprazole sodium products require aqueous stability, alkaline pH control, sterility, and parenteral compatibility.

Is disodium EDTA essential in esomeprazole sodium injection?

It is not necessarily essential in every formulation, but it can reduce the effect of trace metals on degradation. Removing it would require comparative stability, impurity, and container-closure data.

Is a ready-to-use esomeprazole sodium infusion commercially feasible?

Yes, but it presents greater stability, packaging, and regulatory challenges than a lyophilized vial. Its commercial value depends on achieving sufficient shelf life and demonstrating a measurable hospital workflow advantage.

Can esomeprazole sodium be terminally sterilized?

Terminal sterilization may be difficult because heat can accelerate degradation. The feasibility depends on the formulation, container, sterilization cycle, impurity profile, and validated stability data.

What is the most defensible formulation patent strategy for esomeprazole sodium?

The strongest strategy generally combines a defined formulation range with an objective technical result, such as improved shelf life, lower impurity formation, enhanced reconstitution performance, or compatibility with a specified ready-to-use container.

References

1. U.S. Food and Drug Administration. (2023). Nexium I.V. prescribing information.
2. U.S. Food and Drug Administration. (2024). Inactive ingredient database.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
4. National Library of Medicine. (2024). DailyMed: Esomeprazole sodium injection labeling.
5. European Medicines Agency. (2024). Esomeprazole product information.